secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001193125-22-103598
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology appoints Jotin Marango as CFO and Head of Corporate Development
------------------------------------------------------------------------------

- Dr. Marango will assume CFO role effective April 25, 2022, succeeding interim CFO Mark Manfredi.
- Base salary of $425,000; annual bonus target of 40% of base salary.
- Granted option to purchase 397,199 shares, vesting 25% on one-year anniversary and rest over 36 months.
- Dr. Marango previously served as SVP, CFO and CBO at Aptose Biosciences.
- Severance benefits include lump-sum payments and accelerated vesting upon qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/0001193125-22-103598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522103598/d323540d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-103598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer